Strontium ranelate: an effective solution for diverse fracture risks.
Osteoporosis is listed by the WHO among the ten most frequent and socio-economically important, chronic diseases of mankind. The term osteoporosis however comprises a number of different pathophysiological conditions and clinical situations of weakened bones with increased risk of fragility fractures. A modern anti-osteoporotic drug should provide qualified study results proving therapeutic efficacy over this broad range of daily clinical appearances of osteoporosis. The decision for treatment in the individual patients depends no longer only on bone mineral density. Today, the major criterion for decision making is the prospective 10-year risk for fractures. Since this risk is calculated on the basis of age, sex, bone mineral density, prevalent fractures, and a number of other contributing risk factors (Kanis et al., Osteoporos Int 12:989-995, 2001; Kanis et al., Osteoporos Int 19:385-397, 2008), it seems to be of interest to have a look whether the fracture-reducing potency of a drug is influenced by these risk factors. The purpose of this review is to analyze whether the fracture-reducing efficacy of strontium ranelate in patients with osteoporosis can be achieved independently of sex, etiology of osteoporosis, and the major diagnostically relevant risk factors.
Ringe
J D
JD
General Internal Medicine and West-German Osteoporosis Center (WOC), Klinikum Leverkusen, D-51375, Leverkusen, Germany. ringe@klinikum-lev.de
D015992:Body Mass Index; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D020022:Genetic Predisposition to Disease; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000209:etiology / Q000517:prevention & control*; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D013876:Thiophenes / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D005938:Glucocorticoids; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate
J Bone Miner Res. 2006 Apr;21(4):536-42
16598373
Osteoporos Int. 2007 Oct;18(10):1319-28
17566815
Am J Med. 1999 Mar;106(3):311-4
10190380
Lancet. 2006 Jun 17;367(9527):2010-8
16782492
Rheumatol Int. 2010 May;30(7):863-9
20035331
J Bone Miner Res. 2006 Jan;21(1):124-31
16355281
J Bone Miner Res. 2002 Apr;17(4):716-24
11918229
Ann Rheum Dis. 2008 Mar;67(3):335-9
17965119
J Bone Miner Res. 2000 Dec;15(12):2504-12
11127216
J Clin Endocrinol Metab. 2006 Oct;91(10):3908-15
16849417
Arzneimittelforschung. 2010;60(5):267-72
20533764
Calcif Tissue Int. 2001 Oct;69(4):229-34
11730257
Osteoporos Int. 2008 Apr;19(4):399-428
18266020
N Engl J Med. 2004 Jan 29;350(5):459-68
14749454
Bone. 1989;10(6):415-9
2624821
Am J Epidemiol. 1993 Aug 1;138(3):160-9
8356959
N Engl J Med. 2007 Nov 15;357(20):2028-39
18003959
J Bone Miner Res. 2005 Mar;20(3):529-35
15746999
BMJ. 1997 Oct 4;315(7112):841-6
9353503
BMJ. 1994 Sep 17;309(6956):691-5
7950520
J Clin Endocrinol Metab. 2002 Jun;87(6):2460-6
12050200
J Clin Endocrinol Metab. 2005 May;90(5):2816-22
15728210
Bone. 2008 Jan;42(1):129-38
17945546
J Bone Miner Res. 1996 Feb;11(2):293-7
8822354
Eur J Epidemiol. 2000 Mar;16(3):223-9
10870936
N Engl J Med. 2008 Apr 3;358(14):1474-82
18385499
Osteoporos Int. 2007 Apr;18(4):495-503
17253119
Osteoporos Int. 2008 Sep;19(9):1247-50
18604578
Endocrinol Metab Clin North Am. 2007 Jun;36(2):399-419
17543726
Clin Rheumatol. 2007 Apr;26(4):474-84
17122953
J Bone Miner Res. 1994 Jun;9(6):761-9
8079652
J Bone Miner Res. 2000 Jun;15(6):993-1000
10841167
J Bone Miner Res. 1994 Nov;9(11):1671-8
7863817
J Bone Miner Res. 1999 Sep;14(9):1622-7
10469292